Medicinova Inc
MNOV
Get informed when a big investor buys or sells
+ FollowMarket Cap$68.42M
Close$
$0.62
55.3% downside
Current Fair Value
55.3% downsideOvervalued by 55.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $68.42 Million |
|---|---|
| Enterprise Value | $-25,230,465,468.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.24 |
| Beta | 0.61 |
| Outstanding Shares | 49,221,246 |
Return
| Return on Equity | -15.14% |
|---|---|
| Return on Assets | -13.95% |
| Return on Invested Capital | -8.16% |
Valuation & Multiples
| P/E Ratio | -6.4 |
|---|---|
| PEG | 21.71 |
| Price to Sales | 0.23 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | -46.38 |
| Enterprise Value to EBIT | 4.72 |
| Enterprise Value to Net Income | 4 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
$65,000
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$50,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 10.66%▼ 0.31% |
|---|---|
| Total Invested | $6.93M▼ 6.41% |
| Investors Holding | 300% |
ESG Score
No data
About Medicinova Inc
6 employees
CEO: Yuichi Iwaki MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. Its programs include MN-001, MN-166 neurology diseases...